Circulating and Tissue microRNAs as Biomarkers for Ovarian Cancer Prognosis

Parizadeh, Seyed Mostafa; Ghandehari, Maryam; Hasanzadeh, Malihe; Hassanian, Seyed Mahdi; Rezaei-Kalat, Afsaneh; Aghabozorgi, Amirsaeed Sabeti; Rahimi-Kakhki, Rana; Zargaran, Bita; Ferns, Gordon A.; Avan, Amir

doi:10.2174/1389450120666190708100308

Cited by 7 publications

(7 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MicroRNAs (miRNAs) have recently demonstrated promise in the diagnosis of other types of cancer ( Poel et al, 2018 , Montazerian et al, 2018 , Otandault et al, 2019 ) owing to their stability and relative ease of detection in blood samples, allowing minimally invasive, repeated sampling. Importantly miRNAs are aberrantly expressed in a number of cancers ( Pendlebury et al, 2017 , Deb et al, 2018 , Parizadeh et al, 2019 ), including HGSC ( Liu et al, 2019 ), where they have been shown to accelerate tumor migration and invasion ( Liu et al, 2019 ). However reduced expression of miRNAs can have the opposite effect, miR182 was associated with higher expression of discoidin domain receptor 2 (DDR2), a tumour promoter, in women with HGSC ( Ramalho et al, 2019 ) and lower circulating levels of miR182 had a worse prognosis ( Ramalho et al, 2019 ) suggesting that miRNAs both positively and negatively regulate tumour growth and disease progression.…”

Section: Discussionmentioning

confidence: 99%

Transcriptomic analysis of patient plasma reveals circulating miR200c as a potential biomarker for high-grade serous ovarian cancer

Hannan

Cohen

Beard

et al. 2022

Gynecologic Oncology Reports

View full text Add to dashboard Cite

Highlights Circulating microRNAs may provide biomarkers for the development of tests to identify women at risk of ovarian cancer. The microRNA miR200c is dysregulated in the circulation of women with high grade serous ovarian cancer. Next generation sequencing of cell free circulating miRNAs provides potential for the development of screening tests.

show abstract

Section: Discussionmentioning

confidence: 99%

Transcriptomic analysis of patient plasma reveals circulating miR200c as a potential biomarker for high-grade serous ovarian cancer

Hannan

Cohen

Beard

et al. 2022

Gynecologic Oncology Reports

View full text Add to dashboard Cite

show abstract

“…MiRNAs are short non-coding RNA sequences from 17 to 25 nucleotides in length, regulating gene expression at the post-transcriptional level [ 73 ]. Aberrant expression of various specific miRNAs has been observed in various tumors, including breast [ 74 , 75 ], lung [ 76 ], colorectal cancer [ 77 ], ovarian [ 78 ], and prostate cancer [ 79 ]. This feature allows not only to distinguish tumor tissue from normal tissue but also to classify tumors according to the tissue origin, and to perform tumor staging [ 80 ], which potentially makes miRNAs a biomarker efficient for prognosing the development of oncological diseases [ 81 ].…”

Section: Exosomal Mirnasmentioning

confidence: 99%

Liquid Biopsy in Diagnosis and Prognosis of Non-Metastatic Prostate Cancer

et al. 2022

View full text Add to dashboard Cite

Currently, sensitive and specific methods for the detection and prognosis of early stage PCa are lacking. To establish the diagnosis and further identify an appropriate treatment strategy, prostate specific antigen (PSA) blood test followed by tissue biopsy have to be performed. The combination of tests is justified by the lack of a highly sensitive, specific, and safe single test. Tissue biopsy is specific but invasive and may have severe side effects, and therefore is inappropriate for screening of the disease. At the same time, the PSA blood test, which is conventionally used for PCa screening, has low specificity and may be elevated in the case of noncancerous prostate tumors and inflammatory conditions, including benign prostatic hyperplasia and prostatitis. Thus, diverse techniques of liquid biopsy have been investigated to supplement or replace the existing tests of prostate cancer early diagnosis and prognostics. Here, we provide a review on the advances in diagnosis and prognostics of non-metastatic prostate cancer by means of various biomarkers extracted via liquid biopsy, including circulating tumor cells, exosomal miRNAs, and circulating DNAs.

show abstract

“…Therefore, effective methods for early diagnosis and grading hepatic fibrosis must be developed. Circulating and exosomal miRNAs could be used as markers for diagnosis or indicators for determining severity of certain diseases and therapeutic effects [97–99]. For example, elevated miR-21, miR-122 and miR-223 in the serum may serve as new biomarkers for liver injury diseases such as liver cancer and chronic hepatitis [100].…”

Section: Using Mirnas To Grade Schistosomiasis-associated Hepatic Fibmentioning

confidence: 99%

The role of microRNAs in the pathogenesis, grading and treatment of hepatic fibrosis in schistosomiasis

et al. 2019

View full text Add to dashboard Cite

Schistosomiasis is a prevalent parasitic disease worldwide. The main pathological changes of hepatosplenic schistosomiasis are hepatic granuloma and fibrosis due to worm eggs. Portal hypertension and ascites induced by hepatic fibrosis are usually the main causes of death in patients with chronic hepatosplenic schistosomiasis. Currently, no effective vaccine exists for preventing schistosome infections. For quite a long time, praziquantel (PZQ) was widely used for the treatment of schistosomiasis and has shown benefit in treating liver fibrosis. However, drug resistance and chemical toxicity from PZQ are being increasingly reported in recent years; therefore, new and effective strategies for treating schistosomiasis-induced hepatic fibrosis are urgently needed. MicroRNA (miRNA), a non-coding RNA, has been proved to be associated with the development of many human diseases, including schistosomiasis. In this review, we present a balanced and comprehensive view of the role of miRNAs in the pathogenesis, grading, and treatment of schistosomiasis-associated hepatic fibrosis. The multiple regulatory roles of miRNAs, such as promoting or inhibiting the development of liver pathology in murine schistosomiasis are also discussed in depth. Additionally, miRNAs may serve as candidate biomarkers for diagnosing liver pathology of schistosomiasis and as novel therapeutic targets for treating schistosomiasis-associated hepatic fibrosis.

show abstract

Circulating and Tissue microRNAs as Biomarkers for Ovarian Cancer Prognosis

Cited by 7 publications

References 109 publications

Transcriptomic analysis of patient plasma reveals circulating miR200c as a potential biomarker for high-grade serous ovarian cancer

Transcriptomic analysis of patient plasma reveals circulating miR200c as a potential biomarker for high-grade serous ovarian cancer

Liquid Biopsy in Diagnosis and Prognosis of Non-Metastatic Prostate Cancer

The role of microRNAs in the pathogenesis, grading and treatment of hepatic fibrosis in schistosomiasis

Contact Info

Product

Resources

About